Clozapine, the antipsychotic long regarded as the gold standard for treatment-resistant schizophrenia, is the drug that just went from requiring monthly blood draws for life to a monitoring schedule that many clinicians can now reduce to annual checks or even less. On February 24, 2025, the FDA officially removed the Risk Evaluation and Mitigation Strategy program that had governed clozapine prescribing for decades, eliminating the mandatory weekly, biweekly, and monthly lab work that kept countless patients tethered to phlebotomy chairs. For someone like a 68-year-old Parkinson’s disease patient struggling with psychosis, this change means the difference between twelve or more needle sticks a year and potentially just one, a shift that sounds minor on paper but reshapes daily life in practice. The decision was not made lightly.
An FDA advisory committee voted 14 to 1 against continuing the REMS program in November 2024, concluding that the agency was unable to determine that the program had a measurable impact or benefit on reducing neutropenia risk beyond what standard drug labeling could accomplish on its own. The American Society of Clinical Psychopharmacology now recommends that clinicians may consider decreasing monitoring frequency after one year and potentially discontinuing routine monitoring after two years in patients without blood count abnormalities. This article covers why the old monitoring system existed, what the actual risk numbers look like, how the new guidelines work in practice, and what this means specifically for dementia and Parkinson’s disease caregivers navigating psychosis treatment options. The implications reach well beyond schizophrenia care.
Table of Contents
- Why Did Clozapine Require Monthly Lab Tests for Decades?
- What the Risk Statistics Actually Show About Clozapine Safety
- What the New Monitoring Guidelines Look Like in Practice
- How Caregivers Should Approach the Clozapine Conversation With Doctors
- Risks That Remain Even Without the REMS Program
- What This Means for Dementia-Related Psychosis Specifically
- Where Clozapine Prescribing Goes From Here
- Conclusion
- Frequently Asked Questions
Why Did Clozapine Require Monthly Lab Tests for Decades?
Clozapine carries a rare but serious risk of agranulocytosis, a condition in which the body’s white blood cell count drops so low that even a minor infection can become fatal. When the drug first came to market, this risk prompted one of the most restrictive prescribing frameworks in American medicine. Patients were required to undergo weekly blood draws measuring their Absolute Neutrophil Count for the first six months, biweekly draws from months six through twelve, and monthly draws indefinitely after that. Prescribers had to be certified, pharmacies had to be certified, and every single ANC result had to be reported to a central registry before the next prescription could be dispensed. Missing a single blood draw meant the pharmacy could not release the medication.
Compare this to warfarin, a blood thinner that can cause fatal bleeding and is prescribed to millions of older adults with far less oversight, or to carbamazepine, an anticonvulsant with its own agranulocytosis risk that has never required a REMS program. The disparity always struck clinicians as disproportionate. The clozapine REMS was not just a monitoring requirement but an entire bureaucratic infrastructure that created delays, gaps in treatment, and administrative headaches that discouraged many psychiatrists from prescribing the drug at all. The result was a stark underuse problem. Despite being one of the most effective antipsychotics available, clozapine was prescribed to only about four percent of schizophrenia patients nationally. For patients with treatment-resistant psychosis, including those with Parkinson’s disease, this meant that the single most effective medication was often the hardest one to actually get.
What the Risk Statistics Actually Show About Clozapine Safety
The numbers behind the FDA’s decision tell a story that may surprise caregivers who have heard only that clozapine is dangerous. Agranulocytosis, the most feared complication, occurs in roughly 0.7 to 0.9 percent of patients. That is not zero, but it is far lower than many people assume. More importantly, 84 percent of all agranulocytosis cases develop within the first three months of treatment, and 96 percent occur within the first six months. After two years of use without any hematological problems, the incidence drops to levels that are progressively lower with each passing year.
Here is the comparison that changed the FDA’s calculus: the risk of clozapine-induced agranulocytosis, estimated at 0.3 to 0.8 percent, is comparable to the agranulocytosis rates associated with other widely prescribed medications that carry no monitoring requirements whatsoever. Drugs like methimazole for thyroid disorders and certain antibiotics have similar or higher rates of this same complication, yet no one requires monthly blood draws to continue taking them. However, these statistics come with an important caveat for dementia caregivers. The favorable risk profile after the first year applies specifically to patients who have had no abnormal blood counts during that period. If a patient has experienced even a mild neutropenia episode, the risk calculus changes, and more frequent monitoring remains warranted. Clinicians are now solely responsible for making these judgment calls without the REMS infrastructure guiding them, which means patients and families need to be informed participants in the conversation about monitoring frequency.
What the New Monitoring Guidelines Look Like in Practice
With the REMS program gone, the American Society of Clinical Psychopharmacology has stepped in with practical guidance. For at least the first year on clozapine, they recommend following the ANC monitoring schedule outlined in the drug’s labeling, which still calls for weekly checks in the initial months. After one year without hematological issues, clinicians may consider reducing the monitoring frequency. After two years with clean blood counts, clinicians may consider discontinuing routine ANC monitoring altogether, though periodic checks during regular medical visits remain a reasonable precaution. Consider a practical example. A 72-year-old woman with Parkinson’s disease psychosis starts clozapine in March 2025. Under the old system, she would have needed weekly blood draws through September 2025, biweekly draws through March 2026, and monthly draws for the rest of her life, each one requiring a trip to a lab or clinic.
Under the new guidance, her neurologist or psychiatrist might transition her to quarterly monitoring by mid-2026 and annual monitoring by 2027, assuming her blood counts remain normal. For a patient already managing the daily challenges of Parkinson’s, eliminating ten or more annual lab visits is a meaningful reduction in treatment burden. The critical change is who makes the call. There is no longer a centralized registry gatekeeper that must approve each prescription. No more mandatory Patient Status Forms or portal approvals. Prescribers no longer need special certification. Pharmacies no longer need certification to dispense the drug. The monitoring decision now rests entirely with the treating clinician, which gives good doctors more flexibility but also means patients and caregivers should be proactive in discussing what monitoring schedule makes sense for their individual situation.
How Caregivers Should Approach the Clozapine Conversation With Doctors
The removal of the REMS creates a tradeoff that dementia caregivers should understand clearly. On one side, reduced monitoring means fewer disruptions, less physical discomfort, and fewer logistical hurdles for patients who may already find medical appointments distressing or difficult to attend. On the other side, the absence of a mandatory system means that appropriate monitoring only happens if the prescriber and patient actively maintain it. There is no external safety net catching missed lab work. For families managing Parkinson’s disease psychosis, the comparison with other treatment options matters. Pimavanserin, marketed as Nuplazid, is the only FDA-approved drug specifically for Parkinson’s disease psychosis, but it does not work for everyone and carries its own concerns including a boxed warning about increased mortality in elderly dementia patients, a warning that also applies to clozapine and all antipsychotics.
Quetiapine is commonly used off-label but often at the cost of increased sedation and cognitive dulling. Clozapine, despite its blood count risks, is considered by many movement disorder specialists to be the most effective option for Parkinson’s psychosis precisely because it causes the least worsening of motor symptoms. The loosening of monitoring requirements may finally make it a realistic option for patients whose caregivers could not manage the previous schedule. The practical step for caregivers is straightforward. If your loved one has treatment-resistant psychosis, whether from schizophrenia, Parkinson’s disease, or Lewy body dementia, ask the prescribing physician directly whether clozapine is now a viable option given the relaxed monitoring requirements. Come prepared to discuss the patient’s ability to tolerate blood draws, the logistics of lab visits, and what monitoring schedule the doctor considers appropriate for the first year and beyond.
Risks That Remain Even Without the REMS Program
The end of mandatory monitoring does not mean clozapine is suddenly risk-free. The drug still causes neutropenia in approximately 3 to 3.8 percent of patients, and while most cases are manageable, some progress to the life-threatening agranulocytosis that prompted the REMS in the first place. The first three months of treatment remain the highest risk period regardless of any regulatory changes. There are also non-hematological risks that caregivers should be aware of. Clozapine is associated with significant metabolic side effects including weight gain, elevated blood sugar, and increased cholesterol levels. It can cause myocarditis, particularly in the early weeks of treatment.
Sedation is common and can be pronounced in elderly patients. For someone with dementia or Parkinson’s disease, increased sedation and metabolic disruption are not trivial concerns, and they require their own monitoring independent of blood counts. One limitation of the current situation that deserves attention: the removal of the REMS happened relatively suddenly, and many healthcare systems are still adjusting their internal protocols. Some pharmacies may continue to require ANC results out of an abundance of caution or simply because they have not updated their procedures. Some electronic health record systems still have clozapine REMS alerts built in. Caregivers may encounter friction during this transition period, and it helps to know that the requirement is genuinely gone at the federal level even if local practices have not fully caught up.
What This Means for Dementia-Related Psychosis Specifically
Psychosis affects up to 50 percent of people with Parkinson’s disease at some point during their illness, and it is a common feature of Lewy body dementia. For these patients, the visual hallucinations and delusions are not just distressing but are among the leading reasons for nursing home placement. Effective treatment can be the difference between a patient remaining at home with family and requiring institutional care.
A Parkinson’s patient in a rural community, for instance, who previously could not access clozapine because the nearest certified pharmacy was an hour away and weekly lab visits were impossible, may now find the drug accessible for the first time. The FDA’s decision has specific implications for movement disorder clinics and geriatric psychiatry practices that serve these populations. Without the REMS barriers, clinicians in these specialties can initiate clozapine more readily and tailor the monitoring schedule to what an elderly patient can realistically manage, potentially opening the door for thousands of patients who were effectively locked out of the most effective treatment for their condition.
Where Clozapine Prescribing Goes From Here
The expectation among psychiatric and neurological professional organizations is that clozapine prescribing will increase meaningfully now that the REMS barrier is gone. How much it increases, and how quickly, depends largely on whether prescribers who avoided clozapine for logistical reasons are willing to re-engage with the drug now that the administrative burden has been lifted. Medical education will also need to catch up, since a generation of clinicians trained under the assumption that clozapine was simply too cumbersome to prescribe routinely.
For the dementia care community, the most important development to watch is whether movement disorder specialists and geriatric psychiatrists begin incorporating clozapine into treatment algorithms more aggressively for Parkinson’s disease psychosis and Lewy body dementia. If they do, caregivers should expect to have more conversations about blood monitoring, but far fewer actual blood draws than would have been required even a year ago. The drug that once demanded a lifetime of monthly lab visits now asks, for many long-term patients, only an annual check.
Conclusion
The FDA’s removal of the clozapine REMS program in February 2025 represents one of the most significant practical changes in psychosis treatment in years. For patients and caregivers dealing with treatment-resistant schizophrenia, Parkinson’s disease psychosis, or Lewy body dementia, it means the most effective antipsychotic available is no longer gated behind a monitoring system that many patients and doctors found prohibitively burdensome. The risk of agranulocytosis has not changed, but the recognition that mandatory lifelong blood monitoring was not reducing that risk has finally led to a more proportionate approach.
Caregivers should take this as an opportunity to revisit treatment options with their loved one’s physician. If clozapine was previously ruled out because of the monitoring demands, it may now be feasible. The first year still requires careful blood count surveillance, but beyond that, the path to reduced monitoring is clear for patients who tolerate the drug well. As always, the decision should be made in partnership with a knowledgeable prescriber who can weigh the individual patient’s risks, benefits, and practical circumstances.
Frequently Asked Questions
Is clozapine approved for dementia-related psychosis?
Clozapine is not specifically FDA-approved for dementia-related psychosis. It is approved for treatment-resistant schizophrenia. However, it is used off-label for Parkinson’s disease psychosis and is considered by many specialists to be effective for psychosis associated with Lewy body conditions. Like all antipsychotics, it carries a boxed warning about increased mortality risk in elderly dementia patients.
Can my loved one stop getting blood tests entirely now?
Not immediately. The American Society of Clinical Psychopharmacology recommends following the label’s ANC monitoring schedule for at least the first year. After one year without blood count abnormalities, clinicians may reduce the frequency. After two years with normal results, routine monitoring may potentially be discontinued. The decision is now up to the prescribing doctor rather than a federal registry.
How dangerous is agranulocytosis from clozapine?
Agranulocytosis occurs in roughly 0.7 to 0.9 percent of clozapine patients, with the vast majority of cases appearing in the first six months. The condition can be fatal if not caught, but with appropriate monitoring during the high-risk period, most cases are detected and managed by stopping the drug. After two years without incident, the risk drops to very low levels.
Why was clozapine so underused before this change?
Despite being the most effective antipsychotic for treatment-resistant psychosis, clozapine was prescribed to only about 4 percent of eligible schizophrenia patients. The mandatory REMS program, with its required weekly to monthly blood draws, certified prescribers, certified pharmacies, and registry reporting, created logistical barriers that discouraged both doctors and patients from using it.
Will my pharmacy still require blood test results before dispensing clozapine?
The federal REMS requirement is gone, so pharmacies are no longer mandated to verify ANC results before dispensing. However, some pharmacies and health systems may continue their own internal policies during the transition period. If you encounter delays, it may help to inform the pharmacy that the FDA removed the REMS requirement effective February 24, 2025.
Does this change affect people already taking clozapine?
Yes. Patients who have been on clozapine for more than two years without blood count problems may now be candidates for reduced or discontinued routine monitoring, at their prescriber’s discretion. They also no longer need to be enrolled in the REMS registry or submit Patient Status Forms before each prescription fill.
